[go: up one dir, main page]

AR034137A1 - Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria - Google Patents

Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria

Info

Publication number
AR034137A1
AR034137A1 ARP010103806A ARP010103806A AR034137A1 AR 034137 A1 AR034137 A1 AR 034137A1 AR P010103806 A ARP010103806 A AR P010103806A AR P010103806 A ARP010103806 A AR P010103806A AR 034137 A1 AR034137 A1 AR 034137A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
optionally
different
same
Prior art date
Application number
ARP010103806A
Other languages
English (en)
Inventor
Valeria Pittala
Daniele Fancelli
Mario Varasi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24549630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR034137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR034137A1 publication Critical patent/AR034137A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un compuesto de biciclo-pirazol de fórmula (1), en la cual: R y R1, iguales o diferentes, son independientemente un átomo de hidrógeno o un grupo opcionalmente sustituido seleccionado entre R', -COR', -COOR', -CONHR', -CONR'R'', -NH-C(=NH)NHR', -C(=NH)NHR'. -SO2R', -SO2NHR', o -SO2NR'R''; en donde R' y R'', iguales o diferentes, son seleccionados independientemente entre hidrógeno o arilo alquilo C1-6, cicloalquilo C3-6, arilo o alquilo C1-6, rectos o ramificados, opcional y adicionalmente sustituido, o R' y R'' tomados juntos forman una cadena alquileno C4-6; Ra, Rb, Rc y Rd, iguales o diferentes, son seleccionados independientemente entre hidrógeno, grupos -CH2OR', aril- alquilo C1-6, aril- alquilo C1-6, rectos o ramificados, opcional- y adicionalmente sustituidos, en donde R' es como se definió más arriba o Ra y Rb y/o Rc y Rd, tomados junto con el átomo de carbono al cual está unidos, forman un grupo cicloalquilo C3-6 opcionalmente sustituido; m y n, cada uno independientemente, representa 0 o un número entero de 1 a 2, con la condición de que m + n sea menor que, o igual a, 2 (m + n </= 2); y la sal farmacéuticamente aceptable del mismo. Su uso, un procedimiento para prepararlo, una composición farmacéutica que lo comprende, y una biblioteca química combinatoria que comprende una pluralidad de miembros de fórmula (2) en donde: R y R1, iguales o diferentes, son independientemente un átomo de hidrógeno o un grupo sustituido opcionalmente seleccionado entre R', -COR', -COOR', -CONHR', -CONR'R'', NH-C(=NH)NHR', -C(=NH)NHR', -SO2R', -SO2NHR', o -SO2NR'R'', iguales o diferentes, son seleccionados independientemente entre hidrógeno o arilo alquilo C1-6, cicloalquilo C3-6, arilo o alquilo C1-6, rectos o ramificados, opcional y adicionalmente sustituidos, o R' y R'' tomados juntos forman una cadena alquileno C4-6; Ra, Rb, Rc y Rd, iguales o diferentes, son seleccionados entre hidrógeno, grupos -CH2OR', arilo alquilo C1-6, o alquilo C1-6, rectos o ramificados, opcional y adicionalmente sustituidos, en donde R es como se definió más arriba o Ra y Rb y/o Rc y Rd, tomados junto con el átomos de carbono al cual está unidos, forman un grupo cicloalquilo C3-6 opcionalmente sustituido; m y n, cada uno independientemente, representa 0 o un número entero de 1 a 2, con la condición de que m + n sea menor que, o igual a, 2 (m + n </= 2). Los compuestos de fórmula (1) son útiles para el tratamiento de enfermedades ligadas a las proteínas quinasas desreguladas.
ARP010103806A 2000-08-10 2001-08-09 Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria AR034137A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63591400A 2000-08-10 2000-08-10

Publications (1)

Publication Number Publication Date
AR034137A1 true AR034137A1 (es) 2004-02-04

Family

ID=24549630

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103806A AR034137A1 (es) 2000-08-10 2001-08-09 Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria

Country Status (29)

Country Link
US (3) US7541354B2 (es)
EP (1) EP1320531B1 (es)
JP (2) JP4555547B2 (es)
KR (1) KR100904157B1 (es)
CN (2) CN1447810A (es)
AR (1) AR034137A1 (es)
AT (1) ATE480539T1 (es)
AU (2) AU2001287654B2 (es)
BR (1) BR0113176A (es)
CA (1) CA2416527C (es)
CY (1) CY1110914T1 (es)
CZ (1) CZ2003591A3 (es)
DE (1) DE60143041D1 (es)
DK (1) DK1320531T3 (es)
EA (1) EA006381B1 (es)
EE (1) EE05405B1 (es)
ES (1) ES2349762T3 (es)
HU (1) HU229824B1 (es)
IL (2) IL153997A0 (es)
MX (1) MXPA03001169A (es)
MY (1) MY148632A (es)
NO (1) NO325530B1 (es)
NZ (1) NZ524475A (es)
PE (1) PE20020274A1 (es)
PL (1) PL213199B1 (es)
PT (1) PT1320531E (es)
SK (1) SK1882003A3 (es)
WO (1) WO2002012242A2 (es)
ZA (1) ZA200301813B (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143041D1 (de) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
MXPA04011320A (es) 2002-05-15 2005-08-16 Johnson & Johnson 3-aminopirazoles triciclicos n-sustituidos como inhibidores del receptor del factor de crecimiento derivado de plaquetas.
JP4751063B2 (ja) * 2002-05-17 2011-08-17 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物
MXPA05000629A (es) * 2002-07-17 2005-04-25 Pharmacia Italia Spa Derivados de pirazol heterobiciclico como inhibidores de cinasa.
AU2003244632A1 (en) * 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20060135508A1 (en) * 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004013146A1 (en) * 2002-07-25 2004-02-12 Pharmacia Italia S.P.A Condensed heterocyclic pyrazole derivatives as kinase inhibitors
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
EP1608364A1 (en) * 2003-03-11 2005-12-28 Pharmacia Italia S.p.A. Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ME00142B (me) 2003-05-22 2010-10-10 Nerviano Medical Sciences Srl Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
JP2007506787A (ja) * 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
ES2357776T3 (es) * 2004-10-27 2011-04-29 Janssen Pharmaceutica Nv Moduladores de cannabionoides de tetrahidro piridinil pirazol.
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006072831A1 (en) 2005-01-10 2006-07-13 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
BRPI0613045A2 (pt) * 2005-07-15 2010-12-14 Hoffmann La Roche aminas cÍclicas fundidas a heteroarila
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200736255A (en) * 2005-12-01 2007-10-01 Elan Pharm Inc 5-(Substituted)-pyrazolopiperidines
US7968583B2 (en) 2005-12-12 2011-06-28 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
EP1968976A1 (en) * 2005-12-12 2008-09-17 NERVIANO MEDICAL SCIENCES S.r.l. Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
DK1979356T3 (da) * 2005-12-21 2013-11-18 Pfizer Prod Inc Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
WO2007099166A1 (en) * 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
JP5250432B2 (ja) * 2006-03-03 2013-07-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なビシクロピラゾール
WO2007106391A1 (en) * 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
AU2007258527A1 (en) * 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
JP5415271B2 (ja) 2006-10-11 2014-02-12 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としての置換ピロロ−ピラゾール誘導体
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AP2009004958A0 (en) 2007-02-07 2009-08-31 Pfizer 3-amino-pyrrolo [3,4-C] pyrazole - 5 (1H, 4H, 6H) carbaldehyde derivatives as PKC inhibitors
US8293762B2 (en) 2007-02-27 2012-10-23 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors
US8114871B2 (en) * 2007-04-12 2012-02-14 Pfizer Inc. 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
ES2415907T3 (es) 2008-07-24 2013-07-29 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CA2745596A1 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2012080990A1 (en) 2010-12-17 2012-06-21 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
CN102134243A (zh) * 2011-03-04 2011-07-27 中国医学科学院医药生物技术研究所 具有抗肿瘤活性的双环氨基吡唑类衍生物
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
CN103717574B (zh) * 2011-05-04 2017-02-22 福马Tm有限责任公司 用于抑制nampt的新化合物和组合物
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2014351413B2 (en) 2013-11-21 2017-06-01 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
AU2015263884B2 (en) 2014-05-23 2019-11-14 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016109684A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CN104530045A (zh) * 2015-01-14 2015-04-22 中国药科大学 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
AU2016272908B2 (en) 2015-06-04 2021-05-06 Aurigene Oncology Limited Substituted heterocyclyl derivatives as CDK inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3309163A4 (en) 2015-06-15 2019-01-09 UBE Industries, Ltd. SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3478683B1 (en) 2016-06-29 2021-07-21 Novira Therapeutics Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
WO2018005881A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
CA3031585A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
SI3494116T1 (sl) 2017-01-30 2020-02-28 Astrazeneca Ab Modulatorji receptorja estrogena
WO2018222598A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
MA48800A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
MX2020003439A (es) 2017-10-11 2020-07-29 Hoffmann La Roche Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
KR20200083552A (ko) * 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
AU2018388657C1 (en) 2017-12-22 2023-03-23 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
SG11202005791QA (en) * 2017-12-22 2020-07-29 Chemocentryx Inc DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AR114464A1 (es) 2018-04-02 2020-09-09 Chemocentryx Inc PROFÁRMACOS DE ANTAGONISTAS DE C5aR BICÍCLICOS FUSIONADOS
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN110878042B (zh) * 2018-09-05 2021-06-01 新发药业有限公司 一种n-取代基哌啶-3-酮的制备方法
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
AU2019413694B2 (en) * 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
JP7675658B2 (ja) * 2019-04-30 2025-05-13 ヴァロ ヘルス インコーポレイテッド Ｕｓｐ３６の阻害
CA3143349A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
EP4010336B1 (en) * 2019-08-05 2025-04-02 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
EP4081527A4 (en) * 2019-12-24 2024-01-10 Dana-Farber Cancer Institute, Inc. COMBINATION OF A CYCLIN-DEPENDENT KINASE-7 INHIBITOR AND IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
EP4138787A1 (en) 2020-04-24 2023-03-01 Astrazeneca AB Pharmaceutical formulations
US20210330653A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
CN115073471B (zh) * 2021-03-11 2023-03-21 沈阳药科大学 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
CN115057860B (zh) * 2022-05-20 2024-02-09 四川大学华西医院 一种erk抑制剂及其制药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
EP0707585A1 (en) * 1993-07-06 1996-04-24 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
US5508300A (en) * 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6008230A (en) * 1995-10-16 1999-12-28 Fujisawa Pharmaceutical Co., Ltd. Quinoline compounds as H+ -ATPases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
ID26328A (id) 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
DE60143041D1 (de) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1968976A1 (en) * 2005-12-12 2008-09-17 NERVIANO MEDICAL SCIENCES S.r.l. Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors

Also Published As

Publication number Publication date
US20070191386A1 (en) 2007-08-16
NO325530B1 (no) 2008-06-09
DE60143041D1 (de) 2010-10-21
PT1320531E (pt) 2010-10-27
NO20030381D0 (no) 2003-01-24
ES2349762T3 (es) 2011-01-11
EE200300054A (et) 2004-12-15
CA2416527C (en) 2009-12-22
DK1320531T3 (da) 2011-01-03
IL153997A (en) 2014-01-30
EA200300248A1 (ru) 2003-08-28
JP5185243B2 (ja) 2013-04-17
MXPA03001169A (es) 2003-06-30
KR100904157B1 (ko) 2009-06-23
JP4555547B2 (ja) 2010-10-06
IL153997A0 (en) 2003-07-31
EP1320531B1 (en) 2010-09-08
ZA200301813B (en) 2004-06-22
PE20020274A1 (es) 2002-03-31
CN102060857A (zh) 2011-05-18
WO2002012242A2 (en) 2002-02-14
US20030171357A1 (en) 2003-09-11
HUP0300741A2 (hu) 2003-11-28
NO20030381L (no) 2003-02-24
CY1110914T1 (el) 2014-02-12
PL360663A1 (en) 2004-09-20
US20090221632A1 (en) 2009-09-03
SK1882003A3 (en) 2003-06-03
BR0113176A (pt) 2003-06-17
US8273765B2 (en) 2012-09-25
PL213199B1 (pl) 2013-01-31
EE05405B1 (et) 2011-04-15
KR20030027008A (ko) 2003-04-03
EP1320531A2 (en) 2003-06-25
CN1447810A (zh) 2003-10-08
HU229824B1 (en) 2014-08-28
JP2010111677A (ja) 2010-05-20
CA2416527A1 (en) 2002-02-14
US7541354B2 (en) 2009-06-02
WO2002012242A3 (en) 2002-06-06
HUP0300741A3 (en) 2005-12-28
JP2004505977A (ja) 2004-02-26
ATE480539T1 (de) 2010-09-15
EA006381B1 (ru) 2005-12-29
MY148632A (en) 2013-05-15
CZ2003591A3 (cs) 2003-06-18
AU2001287654B2 (en) 2006-12-14
NZ524475A (en) 2004-11-26
AU8765401A (en) 2002-02-18
US7531531B2 (en) 2009-05-12

Similar Documents

Publication Publication Date Title
AR034137A1 (es) Un compuesto de biciclo-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y una biblioteca quimica combinatoria
BR0009338A (pt) Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
PA8547501A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
AR003455A1 (es) Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR036182A1 (es) Conjugados de biomoleculas y 1,4,7,10-tetraazaciclododecanos, un procedimiento para su preparacion, su uso para la preparacion de medios de diagnostico por resonancia magnetica nuclear o radiodiagnostico o para la radioterapia, los agentes farmaceuticos que los contienen, y los conjuntos o kits para
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
YU21803A (sh) Farmaceutski aktivni derivati sulfonamida koji imaju i lipofilne i jonizujuće osobine kao inhibitori protein-junkinaza
ES2181725T3 (es) Inhibidores de hiv proteasa.
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
AR037100A1 (es) Compuesto de pirimidina de anillo fusionado alquinilado, proceso de preparacion, compuestos intermedios, composicion farmaceutica y usi para preparacion de un producto medicinal
EA200000792A3 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
EA200000431A3 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
EA199900135A1 (ru) Производные пиразолопиридина и их применение в качестве фармацевтического препарата
EA200100597A3 (ru) Новые 1,1- и 1,2-дизамещенные циклопропановые соединения, способ их получения и содержащие их фармацевтические композиции
AR040520A1 (es) Derivados de pirazol heterociclicos condensados, como inhibidores de la quinasa
EA200970002A1 (ru) Двойственные молекулы, содержащие пероксидное производное, их синтез и их терапевтические применения
EA200700144A1 (ru) Производные пиридопиримидина, их получение, их применение в терапии
AR124791A1 (es) DERIVADOS DE IMIDAZO[4,5-d]PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN TERAPÉUTICA
ES2075976T3 (es) Derivados de aminoacido y su empleo como agentes antiviricos.
EA200200663A1 (ru) НОВЫЕ СОЕДИНЕНИЯ ОКТАГИДРО-2H-ПИРИДО[1,2-α]ПИРАЗИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ИХ СОДЕРЖАЩИЕ

Legal Events

Date Code Title Description
FG Grant, registration